Ralf Morgenstern
Corporate Officer/Principal at Karolinska Institutet
Profile
Ralf Morgenstern is the founder of NovaSAID AB, which was founded in 2004.
He held the title of Director at NovaSAID AB.
Currently, Dr. Morgenstern is a Professor at Karolinska Institutet.
Ralf Morgenstern active positions
| Companies | Position | Start |
|---|---|---|
| Karolinska Institutet | Corporate Officer/Principal | 2010-05-05 |
Former positions of Ralf Morgenstern
| Companies | Position | End |
|---|---|---|
NovaSAID AB
 NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
NovaSAID AB
NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Health Technology |
- Stock Market
- Insiders
- Ralf Morgenstern